首页 | 本学科首页   官方微博 | 高级检索  
     

MTT法体外药敏实验预测宫颈癌细胞药物敏感性的初步探讨
引用本文:Xiao Y,Li JD,Shi HL,Liu JH,Feng YL,Li MD. MTT法体外药敏实验预测宫颈癌细胞药物敏感性的初步探讨[J]. 癌症, 2007, 26(4): 386-389
作者姓名:Xiao Y  Li JD  Shi HL  Liu JH  Feng YL  Li MD
作者单位:华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心妇科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心妇科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心妇科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心妇科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心妇科,广东,广州,510060
摘    要:背景与目的:近年来,宫颈癌新辅助化疗逐渐受到重视,应用广泛,但不同个体对不同化疗药物敏感性不同.本研究通过宫颈癌体外药敏实验来预测肿瘤细胞对化疗药物的敏感性,为临床筛选对宫颈癌相对敏感的化疗药物提供参考依据.方法:采用MTT法测定9种药物对32例宫颈癌患者的原代培养癌细胞的抑制水平.结果:①宫颈癌细胞对9种药物的敏感性依次为:力扑素>泰素>卡铂>异环磷酰胺>鬼臼乙叉甙>氟尿嘧啶>顺铂>博来霉素>环磷酰胺,力扑素、泰素和卡铂对肿瘤细胞的平均抑制率(IR)较高,分别为56.56%、55.66%和46.81%,与其它药物相比,差异有显著性(P<0.05).②对Ⅰ b1期宫颈癌细胞,泰素、力扑素和卡铂IR值较其它药物高,分别为58.71%、53.00%和49.25%;对Ⅰ b2期宫颈癌细胞,力扑素和泰素的IR值较其它药物高,分别为65.26%和50.06%.③对于宫颈中分化鳞癌细胞,泰素、力扑素和卡铂IR值较其它药物高,分别为52.01%、49.21%和40.24%;对低分化鳞癌细胞,力扑素、泰素和卡铂的IR值较其它药物高,分别为61.16%、60.62%和48.75%.结论:①MTT法作为一种应用广泛的药敏实验方法,对宫颈癌新辅助化疗筛选敏感药物、选择临床化疗方案有一定的参考价值.②力扑素、泰素和卡铂对宫颈癌细胞较其它药物敏感.

关 键 词:MTT  宫颈肿瘤  鳞状细胞癌  药物筛选  体外实验  新辅助化疗
文章编号:1000-467X(2007)04-0386-04
修稿时间:2006-09-28

Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer
Xiao Yan,Li Jun-Dong,Shi Hong-Liu,Liu Ji-Hong,Feng Yan-Ling,Li Meng-Da. Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer[J]. Chinese journal of cancer, 2007, 26(4): 386-389
Authors:Xiao Yan  Li Jun-Dong  Shi Hong-Liu  Liu Ji-Hong  Feng Yan-Ling  Li Meng-Da
Affiliation:1. State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China; 2. Department of Gynecology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, P. R. China; 3. Research Department, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, P. R. China
Abstract:BACKGROUND & OBJECTIVE: In recent years, the neoadjuvant chemotherapy for cervical cancer has evoked more and more attention and has been used widely. But the chemosensitivity of individuals to various antitumor drugs is different. This study was to investigate the chemosensitivity of cervical cancer cells to antitumor drugs using in vitro MTT assay chemosensitivity test. METHODS: The sensitivity of fresh human cervical cancer cells from 32 patients to 9 cytotoxic drugs was tested using in vitro MTT assay. RESULTS: The cytotoxic activities of the 9 drugs for cervical cancer were in sequence from high to low as follows: liposomal paclitaxel, taxol, carboplatin (CBP), ifosfamide (IFO), etoposide (VP-16), 5-fluorouracil (5-FU), cisplatin (DDP), bleomycin (BLM), and cyclophosphamide (CTX). Generally, cervical cancer cells were more sensitive to paclitaxel, taxol, and CBP than to other drugs (P<0.05) with inhibition rates of 56.56%, 55.66%, and 46.81%, respectively. Stage Ib1 cervical cancer cells were more sensitive to taxol, paclitaxel, and CBP than to other drugs with inhibition rates of 58.71%, 53.00%, and 49.25%, respectively; stage Ib2 cervical cancer cells were more sensitive to paclitaxel and taxol than to other drugs with inhibition rates of 65.26% and 50.06%. Both moderately and poorly differentiated squamous cell cancer cells were more sensitive to taxol, paclitaxel, and CBP than to other drugs with inhibition rates of 52.01%, 49.21%, and 40.02% for the former, and 60.02%, 61.16%, and 48.75% for the latter. CONCLUSIONS: MTT assay, a sensitive and widely used chemosensitivity testing method, is helpful in sensitive drug screening and neoadjuvant chemotherapy regimen selection for cervical cancer. Cervical cancer cells are more sensitive to paclitaxel, taxol, and CBP than to other tested drugs in this study.
Keywords:MTT assay   Cervical neoplasm   Squamous cell carcinoma   Chemosensitivity test   Neoadjuvant chemotherapy
本文献已被 CNKI 维普 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号